{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:55:24Z","timestamp":1793084124772,"version":"4.5.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["75F40119C10128"],"award-info":[{"award-number":["75F40119C10128"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1195609"],"award-info":[{"award-number":["OPP1195609"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Multiplex bead-based immunoassays (MIAs) are promising tools for simultaneously detecting humoral immunity to multiple targets, potentially playing a crucial role in serosurveillance and vaccine response assessments. However, evaluation of assay performance is paramount prior to widespread use. This study presents a performance evaluation of a pan-filovirus MIA through characterization of the analytical range for the EBOV glycoprotein (GP) target and assessments of assay precision and antigen discrimination. The precision of the MIA was evaluated by comparing the detection of anti-filovirus antibodies at two independent laboratory sites: the University of Hawai\u2019i, Honolulu (UH), and the Institut National de Recherche Biom\u00e9dicale (INRB) in Kinshasa, Democratic Republic of the Congo (DRC). Forty-six samples from Yambuku, DRC, including Ebola virus Disease (EVD) survivors and close contacts, were tested at both sites. Additionally, 907 samples were tested in DRC before and after vaccination with a prophylactic EVD vaccine, ERVEBO. Results demonstrated low variability between laboratories, with intra-assay and inter-laboratory coefficients of variation below predefined thresholds for all filovirus targets included in the multiplex panel. Analyte correlation between sites was high (r\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.86\u20130.92). Longitudinal analysis detected increased EBOV GP reactivity following vaccination, while reactivity to non-vaccine filovirus antigens remained stable, consistent with minimal cross-reactivity in a vaccinated cohort. These findings suggest that this pan-filovirus MIA produces reproducible results across distinct laboratory settings and may serve as a useful tool for comparative serologic investigations, serosurveillance, and evaluation of EBOV vaccine-associated antibody responses.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0356257","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:34:51Z","timestamp":1787247291000},"page":"e0356257","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4490-6248","authenticated-orcid":true,"given":"Olivia A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-605X","authenticated-orcid":true,"given":"Sydney","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Kompany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri Ann S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varney","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merly","family":"Tambu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Halbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3305-7084","authenticated-orcid":true,"given":"Jason","family":"Kindrachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4147-0677","authenticated-orcid":true,"given":"Angelica L.","family":"Barrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamy","family":"Musene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5981-7317","authenticated-orcid":true,"given":"Skylar A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Berestecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9092-2680","authenticated-orcid":true,"given":"Tracy","family":"MacGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Muyembe-Tamfum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didine","family":"Kaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Placide","family":"Mbala-Kingebeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-9067","authenticated-orcid":true,"given":"Anne W.","family":"Rimoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-203X","authenticated-orcid":true,"given":"Axel T.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"pone.0356257.ref001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vascn.2018.01.005","article-title":"Analytical performance of a commercial multiplex Luminex-based cytokine panel in the rat","volume":"91","author":"T Erkens","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"pone.0356257.ref002","first-page":"7","article-title":"Validation of Analytical Methods.","author":"TN. Rao","year":"2018","journal-title":"Calibration and Validation of Analytical Methods - A Sampling of Current Approaches. Rijeka: InTech"},{"issue":"1","key":"pone.0356257.ref003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/2229-4708.72226","article-title":"Bioanalytical method validation: an updated review","volume":"1","author":"G Tiwari","year":"2010","journal-title":"Pharm Methods"},{"issue":"7","key":"pone.0356257.ref004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens11070732","article-title":"Serology as a tool to assess infectious disease landscapes and guide public health policy","volume":"11","author":"AH Haselbeck","year":"2022","journal-title":"Pathogens"},{"issue":"7","key":"pone.0356257.ref005","article-title":"Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: A preliminary report","volume":"13","author":"BK Haun","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0356257.ref006","article-title":"Filoviruses.","volume-title":"Medical Microbiology","author":"HK. Feldmann","year":"1996","edition":"4"},{"key":"pone.0356257.ref007","unstructured":"Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271\u201393."},{"issue":"8011","key":"pone.0356257.ref008","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(77)92000-1","article-title":"Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire","volume":"1","author":"KM Johnson","year":"1977","journal-title":"Lancet"},{"key":"pone.0356257.ref009","volume-title":"Ebola disease caused by Bundibugyo virus","author":"WH Organization","year":"2026"},{"issue":"1","key":"pone.0356257.ref010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jiph.2023.10.020","article-title":"Case fatality rate for Ebola disease, 1976\u20132022: A meta-analysis of global data","volume":"17","author":"J Izudi","year":"2024","journal-title":"J Infect Public Health"},{"issue":"12","key":"pone.0356257.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: a snapshot","volume":"17","author":"C Woolsey","year":"2021","journal-title":"PLoS Pathog"},{"issue":"10","key":"pone.0356257.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8101473","article-title":"To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity","volume":"8","author":"AN Pinski","year":"2020","journal-title":"Microorganisms"},{"issue":"10","key":"pone.0356257.ref013","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/pathogens10101330","article-title":"Structural and functional aspects of Ebola virus proteins","volume":"10","author":"S Jain","year":"2021","journal-title":"Pathogens"},{"issue":"3","key":"pone.0356257.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9030190","article-title":"Development of pandemic vaccines: ERVEBO case study","volume":"9","author":"J Wolf","year":"2021","journal-title":"Vaccines"},{"issue":"24","key":"pone.0356257.ref015","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"J-J Muyembe","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0356257.ref016","article-title":"Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo","volume":"119","author":"NA Hoff","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0356257.ref017","doi-asserted-by":"crossref","first-page":"127684","DOI":"10.1016\/j.vaccine.2025.127684","article-title":"Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years","volume":"64","author":"LI Mayerlen","year":"2025","journal-title":"Vaccine"},{"issue":"22","key":"pone.0356257.ref018","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2017.01.068","article-title":"Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice","volume":"36","author":"AT Lehrer","year":"2018","journal-title":"Vaccine"},{"key":"pone.0356257.ref019","doi-asserted-by":"crossref","first-page":"703986","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant protein filovirus vaccines protect cynomolgus macaques from Ebola, Sudan, and Marburg Viruses","volume":"12","author":"AT Lehrer","year":"2021","journal-title":"Front Immunol"},{"issue":"39","key":"pone.0356257.ref020","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1016\/j.vaccine.2021.08.003","article-title":"Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant","volume":"39","author":"KB Preston","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"pone.0356257.ref021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/immuno3040022","article-title":"High-avidity anti-filovirus IgG elicited using protein subunit vaccines does not correlate with protection","volume":"3","author":"CA Williams","year":"2023","journal-title":"Immuno"},{"issue":"10","key":"pone.0356257.ref022","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.cmi.2020.06.024","article-title":"Validation of a commercially available SARS-CoV-2 serological immunoassay","volume":"26","author":"B Meyer","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"pone.0356257.ref023","unstructured":"Guideline I. Validation of analytical procedures Q2 (R1). Geneva, Switzerland: ICH; 2022."},{"issue":"5","key":"pone.0356257.ref024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cytob.21116","article-title":"Determination of optimal replicate number for validation of imprecision using fluorescence cell-based assays: proposed practical method","volume":"84","author":"BH Davis","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"12","key":"pone.0356257.ref025","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1016\/j.xphs.2022.05.017","article-title":"Lyophilized filovirus glycoprotein vaccines: peroxides in a vaccine formulation with polysorbate 80-containing adjuvant are associated with reduced neutralizing antibody titers in both mice and non-human primates","volume":"111","author":"KB Preston","year":"2022","journal-title":"J Pharm Sci"},{"key":"pone.0356257.ref026","article-title":"Detection of Marburg virus antibodies 25 years after outbreak in Watsa, Democratic Republic of the Congo","author":"S Merritt","year":"2026","journal-title":"J Infect Dis"},{"key":"pone.0356257.ref027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.acc.2019.01.006","article-title":"A practical guide to validation and verification of analytical methods in the clinical laboratory","volume":"90","author":"J Pum","year":"2019","journal-title":"Adv Clin Chem"},{"key":"pone.0356257.ref028","volume-title":"ICH Q2(R2) guideline on validation of analytical procedures - Step 5 - Revision 1","author":"EM Agency","year":"2023"},{"key":"pone.0356257.ref029","doi-asserted-by":"crossref","first-page":"115154","DOI":"10.1016\/j.jviromet.2025.115154","article-title":"Comparison of EBOV GP IgG antibody reactivity: results from two immunoassays in the Democratic Republic of the Congo","volume":"336","author":"S Merritt","year":"2025","journal-title":"J Virol Methods"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:34:57Z","timestamp":1787247297000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356257"}},"subtitle":[],"editor":[{"given":"Masahiro","family":"Kajihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0356257","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}